Comparing the current results to its competitors, Aditxt Inc reported Revenue increase in the 1 quarter 2026 by 1120 % year on year. The sales growth was above Aditxt Inc 's competitors' average revenue growth of 12.51 %, achieved in the same quarter.
Aditxt Inc , slower than the average decrease reported by the company's competitors of -55.47 %. recorded a net loss and most of the company's competitors saw a decline in earnings by -55.47 %
July 24, 2025
: Aditxt, Inc. (NASDAQ: ADTX), a company known for its commitment to accelerating health innovations, has announced a milestone achievement by its subsidiary, Pearsanta, Inc. Pearsanta has received an invitation to submit a full proposal for the Congressionally Directed Medical Research Programs (CDMRP) Ovarian Cancer Research Program (OCRP) Pilot Award, funded by the U.S. Department of Defense. This opportunity signifies a pertinent step forward in the development of the Mitomic Ovarian Test, aimed at enhancing early-stage diagnosis of ovarian cancer.Ovarian cancer remains a formidable challenge in women s health, with early detection being crucial for improved prognoses. Current diagnostic methods are ofte...
April 12, 2025
Aditxt Weekly Update: Navigating Compliance and Market Dynamics In a recent update released from Mountain View, California, Aditxt, Inc. (NASDAQ: ADTX) shared pivotal developments in its ongoing journey as a social innovation platform committed to accelerating promising health innovations. A critical focus of the update was the company’s regained compliance with Nasdaq s minimum bid price requirements, reassuring investors and stakeholders about its adherence to the Nasdaq Capital Markets listing standards.The announcement comes at a crucial time for Aditxt, which has attracted attention not only for its innovative efforts but also for its financial performance. Despite regaining compliance, a closer exami...
April 11, 2025
Aditxt Regains Compliance with Nasdaq as Financial Performance Shows Improvement MOUNTAIN VIEW, Calif. Aditxt, Inc. (NASDAQ: ADTX), a company dedicated to accelerating promising health innovations through a social innovation platform, recently announced significant updates that are poised to impact its standing in the market. In its latest Aditxt Weekly Update, the company highlighted the critical news of regaining compliance with the Nasdaq Capital Market s listing requirements, specifically the minimum bid price requirement.This development comes as a relief to investors and stakeholders, confirming Aditxt’s commitment to meeting the regulatory standards set forth by Nasdaq. Compliance with these listi...
October 10, 2024
In recent months, Aditxt, Inc. has emerged as a key player in the healthcare landscape, particularly through its strategic acquisition of Appili Therapeutics and the clinical initiatives undertaken by its subsidiary, Pearsanta, Inc. This article delves into the implications of these developments, particularly focusing on Appili’s upcoming shareholder meeting to vote on the acquisition, Pearsanta’s commitment to early detection of prostate cancer, and Aditxt’s broader strategy to facilitate healthcare innovations. As the pharmaceutical industry evolves, the integration of innovative strategies is crucial for sustaining growth and advancing patient care. This article expounds on two significant developm...
August 7, 2024
Aditxt and Subsidiary Pearsanta Make Strides in Ovarian Cancer Detection and Regain Nasdaq Compliance Aditxt, Inc. (Aditxt) (NASDAQ: ADTX), a frontrunner in health innovation, recently announced a series of significant developments that underscore its commitment to enhancing patient outcomes through early disease detection and pioneering health technologies. In a recent press release, Aditxt s subsidiary, Pearsanta, Inc. (Pearsanta), revealed its submission of a proposal for the Clinical Trial Translational Endpoints Research Award to the Congressionally Directed Medical Research Programs (CDMRP) of the Department of Defense. This proposal aims to validate a groundbreaking assay for early detection of ovari...
July 25, 2024
MOUNTAIN VIEW, Calif. Aditxt, Inc. (NASDAQ: ADTX), a biotechnology company dedicated to discovering, developing, and deploying innovative health solutions, announced that it has signed a second Amending Agreement (the Amending Agreement) with Appili Therapeutics Inc. (TSX: APLI; OTCPink: APLIF), a biopharmaceutical company specializing in the development of treatments and vaccines for infectious diseases and medical countermeasures.The agreement brings Aditxt one step closer to completing its acquisition of Appili Therapeutics, with both companies targeting a closing date of September 30. This acquisition will potentially bring together Aditxt s technological prowess and Appili s expertise in infectious dis...
January 2, 2024
Aditxt, Inc. Reinstated in Compliance with Nasdaq Stockholders Equity Requirement, Setting a Path to GrowthAditxt, Inc., a renowned health innovation company dedicated to discovering, developing, and deploying groundbreaking medical solutions, has overcome a crucial hurdle by regaining compliance with the minimum stockholders equity requirement set by The Nasdaq Stock Market LLC (Nasdaq). The company has received confirmation from the Nasdaq Hearing Panel, solidifying its position to chart a path of sustained growth. This milestone achievement, subject to a mandatory panel monitor until December 29, 2024, indicates Aditxt s commitment to meeting stringent market regulations and underlines its potential to co...
AbbVie Inc operates primarily as a global biopharmaceutical company, focusing on the research, development, manufacturing, and commercialization of advanced therapies and medications in critical areas such as immunology, oncology, neuroscience, and virology. The company aims to improve patient outcomes and address unmet medical needs by leveraging its scientific expertise and capabilities while providing value to stakeholders in the healthcare industry.
Ascendis Pharma is a pharmaceutical company that focuses on developing innovative therapies for rare diseases using its proprietary TransCon technology platform. They aim to improve patient outcomes by providing long-acting, once-weekly or once-monthly treatments. With a focus on rare endocrine diseases, they aim to address the unmet medical needs of patients through their unique approach to drug development.
Eton Pharmaceuticals Inc operates as a specialty pharmaceutical company, focusing on the development and commercialization of innovative drug products. Their business model involves identifying market opportunities, acquiring or licensing drug candidates, and then developing and marketing these products to cater to specific patient needs.
Greenwich Lifesciences Inc's business model focuses on the research, development, and commercialization of innovative therapies in the field of oncology.
Immunovant Inc is a biopharmaceutical company focused on developing and commercializing therapies for autoimmune diseases by leveraging their expertise in research and development, clinical trials, and regulatory approvals. Their business model revolves around discovering innovative treatments, conducting rigorous testing, and seeking regulatory clearance to bring their products to market and improve patient outcomes.
Sources:
Aditxt Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Aditxt Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
